<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899206</url>
  </required_header>
  <id_info>
    <org_study_id>HUB-FC-2020-01</org_study_id>
    <nct_id>NCT04899206</nct_id>
  </id_info>
  <brief_title>Angiotensin Agents and Reduction of Antidepressant Drugs' Prescription</brief_title>
  <official_title>Angiotensin Agents and Reduction of Antidepressant Drugs' Prescription: A Cohort Study Using Real-World Data.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sebastian Videla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut d'Investigació Biomèdica de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Català de la Salut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective cohort study will be performed by analyzing data obtained from the Catalan&#xD;
      Southern Metropolitan data warehouse system, which collects data from both hospitalized and&#xD;
      primary care patients from the Bellvitge University Hospital's area of influence. The&#xD;
      investigators will begin by gathering information only on patients treated with&#xD;
      antihypertensive drugs, which then will be stratified in two groups: 1) Angiotensin Agents&#xD;
      group; 2) Other Antihypertensive Agents (Non-Angiotensin Agents) group. Afterwards, a&#xD;
      separated analysis will be performed to assess the effects of ARBs and ACEIs separately on&#xD;
      the prescription of antidepressant drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertension is a multifactorial disease and an important risk factor for cardiovascular and&#xD;
      cerebrovascular diseases. Also, major depression is commonly found on these patients.&#xD;
      Together, they represent a substantial burden for patients and their families, with an&#xD;
      increased morbimortality and reduced life-quality. It also has a major social impact by&#xD;
      increasing healthcare assistance demand and by affecting patients' daily-life productivity,&#xD;
      therefore generating direct and indirect health-associated costs.&#xD;
&#xD;
      The Renin-Angiotensin System is one of the known pathways that modulate systemic and central&#xD;
      nervous system inflammation. Basic research studies have shown ARBs-related allosteric&#xD;
      changes on receptors implicated on the pathophysiology of schizophrenia and depression, and&#xD;
      also a pharmacological reversal of depression-like behavior in rats after the administration&#xD;
      of losartan. Human research studies have also presented evidence that points towards an&#xD;
      antidepressant effect of some antihypertensive drugs.&#xD;
&#xD;
      A retrospective cohort study will be performed by analyzing data obtained from the Catalan&#xD;
      Southern Metropolitan data warehouse system, which collects data from both hospitalized and&#xD;
      primary care patients from the Bellvitge University Hospital's area of influence. The&#xD;
      investigators will begin by gathering information only on patients treated with&#xD;
      antihypertensive drugs, which then will be stratified in two groups: 1) Angiotensin Agents&#xD;
      group; 2) Other Antihypertensive Agents (Non-Angiotensin Agents) group. Afterwards, a&#xD;
      separated analysis will be performed to assess the effects of ARBs and ACEIs separately on&#xD;
      the prescription of antidepressant drugs.&#xD;
&#xD;
      The primary objective is to study if being exposed to angiotensin agents is associated with&#xD;
      the prescription of antidepressant drugs. Secondary objectives are as follows:&#xD;
&#xD;
      I. For ARBs:&#xD;
&#xD;
        1. To estimate the prevalence of concomitant exposure to ARBs and to antidepressant drugs&#xD;
           in patients with hypertension.&#xD;
&#xD;
        2. To estimate the incidence of antidepressant drugs withdrawal in patients concomitantly&#xD;
           treated with ARBs and antidepressant drugs.&#xD;
&#xD;
        3. To estimate the incidence of antidepressant drugs initiation in patients with&#xD;
           hypertension treated with ARBs.&#xD;
&#xD;
      II. For ACEIs:&#xD;
&#xD;
        1. To estimate the prevalence of concomitant exposure to ACEIs and to antidepressant drugs&#xD;
           in patients with hypertension.&#xD;
&#xD;
        2. To estimate the incidence of antidepressant drugs withdrawal in patients concomitantly&#xD;
           treated with ACEIs and antidepressant drugs.&#xD;
&#xD;
        3. To estimate the incidence of antidepressant drugs initiation in patients with&#xD;
           hypertension treated with ACEIs.&#xD;
&#xD;
      III. For Other Antihypertensive Drugs (i.e., non-angiotensin agents: CCBs, β-blockers, and&#xD;
      diuretics):&#xD;
&#xD;
        1. To estimate the prevalence of concomitant exposure to Other Antihypertensive Drugs and&#xD;
           to antidepressant drugs in patients with hypertension.&#xD;
&#xD;
        2. To estimate the incidence of antidepressant drugs withdrawal in patients concomitantly&#xD;
           treated with Other Antihypertensive Drugs and antidepressant drugs.&#xD;
&#xD;
        3. To estimate the incidence of antidepressant drugs initiation in patients with&#xD;
           hypertension treated with Other Antihypertensive Drugs.&#xD;
&#xD;
      IV. To perform an exploratory comparative analysis among the different antihypertensive&#xD;
      drugs' arms.&#xD;
&#xD;
      The protocol (Final Version: February 18th, 2021) was approved by the local Institutional&#xD;
      Review Board (Ethic-and-Clinical-Investigation- Committee, code HUB-FC-2020-01, date April&#xD;
      20th, 2021). The study findings will be submitted to peer-reviewed journals and presented at&#xD;
      relevant national and international scientific meetings.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 12, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>38 Days</target_duration>
  <primary_outcome>
    <measure>Patients treated with antihypertensive drugs</measure>
    <time_frame>3 years</time_frame>
    <description>Number of patients under treatment with antihypertensive drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients treated with an antidepressant drug</measure>
    <time_frame>3 years</time_frame>
    <description>Number of patients under treatment with antidepressant drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients diagnosed with Hypertension</measure>
    <time_frame>3 years</time_frame>
    <description>Number of patients diagnosed with Hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients diagnosed with Depression</measure>
    <time_frame>3 years</time_frame>
    <description>Number of patients diagnosed with Depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients treated with ARBs</measure>
    <time_frame>3 years</time_frame>
    <description>Number of patients treated with ARBs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients treated with ACEIs</measure>
    <time_frame>3 years</time_frame>
    <description>Number of patients treated with ACEIs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients treated with other antihypertensive drugs</measure>
    <time_frame>3 years</time_frame>
    <description>Number of patients treated with other antihypertensive drugs (i.e., non-ARBs and non-ACEIs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients treated with Amitriptyline</measure>
    <time_frame>3 years</time_frame>
    <description>Number of patients treated with Amitriptyline, since this is an antidepressant drug commonly used to treat neuropathic pain in our usual practice.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients treated with Duloxetine</measure>
    <time_frame>3 years</time_frame>
    <description>Number of patients treated with Duloxetine, since this is an antidepressant drug commonly used to treat neuropathic pain in our usual practice.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>ACE Inhibitors</condition>
  <condition>ARB</condition>
  <condition>Hypertension</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>ARBs (without ACEIs)</arm_group_label>
    <description>Hypertensive patients under pharmacological treatment with ARBs (patients may be exposed to ARBs alone or to ARBs combined with non-angiotensin agents, meaning that only ACEIs are excluded)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACEIs (without ARBs)</arm_group_label>
    <description>Hypertensive patients under pharmacological treatment with ACEIs (patients may be exposed to ACEIs alone or to ACEIs combined with non-angiotensin agents, meaning that only ARBs are excluded)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARBs + ACEIs</arm_group_label>
    <description>Hypertensive patients under pharmacological treatment with ARBs and ACEIs (patients are only exposed to a combination of both angiotensin agents)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARB</intervention_name>
    <description>Patients exposed to ARBs.</description>
    <arm_group_label>ARBs (without ACEIs)</arm_group_label>
    <arm_group_label>ARBs + ACEIs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE inhibitor</intervention_name>
    <description>Patients exposed to ACEIs.</description>
    <arm_group_label>ACEIs (without ARBs)</arm_group_label>
    <arm_group_label>ARBs + ACEIs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Other Antihypertensive Drugs</intervention_name>
    <description>Patients exposed to Other Antihypertensive Drugs..</description>
    <arm_group_label>ACEIs (without ARBs)</arm_group_label>
    <arm_group_label>ARBs (without ACEIs)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with antihypertensive drugs within the Bellvitge University Hospital's&#xD;
        influence area (Barcelona's southern metropolitan area).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients that had an antihypertensive drug prescribed between January 1st, 2015 and&#xD;
             December 31st, 2017, whose ATC codes can be obtained from the 'DATA WAREHOUSE'&#xD;
             database&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Both genders&#xD;
&#xD;
          -  Patients with information available on the 'DATA WAREHOUSE' database&#xD;
&#xD;
          -  Patients with a clinical visit or prescription done afterwards the date when the&#xD;
             information for the study was last collected (this way we ensure that the patient&#xD;
             included on the study remained alive after the end of the observation period)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of information about the beginning of treatment with an antihypertensive and/or&#xD;
             with an antidepressant drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastián Videla, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of the Clinical Research Support Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <state>Catalonia</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Annerbrink K, Jönsson EG, Olsson M, Nilsson S, Sedvall GC, Anckarsäter H, Eriksson E. Associations between the angiotensin-converting enzyme insertion/deletion polymorphism and monoamine metabolite concentrations in cerebrospinal fluid. Psychiatry Res. 2010 Sep 30;179(2):231-4. doi: 10.1016/j.psychres.2009.04.018. Epub 2010 May 16.</citation>
    <PMID>20483169</PMID>
  </reference>
  <reference>
    <citation>Aso E, Lomoio S, López-González I, Joda L, Carmona M, Fernández-Yagüe N, Moreno J, Juvés S, Pujol A, Pamplona R, Portero-Otin M, Martín V, Díaz M, Ferrer I. Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer's disease. Brain Pathol. 2012 Sep;22(5):636-53. doi: 10.1111/j.1750-3639.2011.00560.x. Epub 2012 Jan 13.</citation>
    <PMID>22188425</PMID>
  </reference>
  <reference>
    <citation>Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015 Dec 10;11(6):1164-78. doi: 10.5114/aoms.2015.56342. Epub 2015 Dec 11.</citation>
    <PMID>26788077</PMID>
  </reference>
  <reference>
    <citation>Borrajo A, Rodriguez-Perez AI, Diaz-Ruiz C, Guerra MJ, Labandeira-Garcia JL. Microglial TNF-α mediates enhancement of dopaminergic degeneration by brain angiotensin. Glia. 2014 Jan;62(1):145-57. doi: 10.1002/glia.22595.</citation>
    <PMID>24272709</PMID>
  </reference>
  <reference>
    <citation>Brownstein DJ, Salagre E, Köhler C, Stubbs B, Vian J, Pereira C, Chavarria V, Karmakar C, Turner A, Quevedo J, Carvalho AF, Berk M, Fernandes BS. Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials. Aust N Z J Psychiatry. 2018 Jan;52(1):24-38. doi: 10.1177/0004867417721654. Epub 2017 Jul 28.</citation>
    <PMID>28754072</PMID>
  </reference>
  <reference>
    <citation>Can A, Dao DT, Arad M, Terrillion CE, Piantadosi SC, Gould TD. The mouse forced swim test. J Vis Exp. 2012 Jan 29;(59):e3638. doi: 10.3791/3638.</citation>
    <PMID>22314943</PMID>
  </reference>
  <reference>
    <citation>Can A, Dao DT, Terrillion CE, Piantadosi SC, Bhat S, Gould TD. The tail suspension test. J Vis Exp. 2012 Jan 28;(59):e3769. doi: 10.3791/3769.</citation>
    <PMID>22315011</PMID>
  </reference>
  <reference>
    <citation>Cao YY, Xiang X, Song J, Tian YH, Wang MY, Wang XW, Li M, Huang Z, Wu Y, Wu T, Wu YQ, Hu YH. Distinct effects of antihypertensives on depression in the real-world setting: A retrospective cohort study. J Affect Disord. 2019 Dec 1;259:386-391. doi: 10.1016/j.jad.2019.08.075. Epub 2019 Aug 24.</citation>
    <PMID>31470183</PMID>
  </reference>
  <reference>
    <citation>Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF. Special Report: The 1996 Guide for the Care and Use of Laboratory Animals. ILAR J. 1997;38(1):41-48.</citation>
    <PMID>11528046</PMID>
  </reference>
  <reference>
    <citation>Deacon RM. Digging and marble burying in mice: simple methods for in vivo identification of biological impacts. Nat Protoc. 2006;1(1):122-4.</citation>
    <PMID>17406223</PMID>
  </reference>
  <reference>
    <citation>Farmer ME, Kittner SJ, Abbott RD, Wolz MM, Wolf PA, White LR. Longitudinally measured blood pressure, antihypertensive medication use, and cognitive performance: the Framingham Study. J Clin Epidemiol. 1990;43(5):475-80.</citation>
    <PMID>2324788</PMID>
  </reference>
  <reference>
    <citation>Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 13th edition, New York: McGraw-Hill Medical, 2018.</citation>
  </reference>
  <reference>
    <citation>Grover MP, Ballouz S, Mohanasundaram KA, George RA, Sherman CD, Crowley TM, Wouters MA. Identification of novel therapeutics for complex diseases from genome-wide association data. BMC Med Genomics. 2014;7 Suppl 1:S8. doi: 10.1186/1755-8794-7-S1-S8. Epub 2014 May 8.</citation>
    <PMID>25077696</PMID>
  </reference>
  <reference>
    <citation>Kessing LV, Rytgaard HC, Ekstrøm CT, Torp-Pedersen C, Berk M, Gerds TA. Antihypertensive Drugs and Risk of Depression: A Nationwide Population-Based Study. Hypertension. 2020 Oct;76(4):1263-1279. doi: 10.1161/HYPERTENSIONAHA.120.15605. Epub 2020 Aug 24.</citation>
    <PMID>32829669</PMID>
  </reference>
  <reference>
    <citation>Kessing LV, Rytgaard HC, Gerds TA, Berk M, Ekstrøm CT, Andersen PK. New drug candidates for depression - a nationwide population-based study. Acta Psychiatr Scand. 2019 Jan;139(1):68-77. doi: 10.1111/acps.12957. Epub 2018 Sep 4.</citation>
    <PMID>30182363</PMID>
  </reference>
  <reference>
    <citation>Komada M, Takao K, Miyakawa T. Elevated plus maze for mice. J Vis Exp. 2008 Dec 22;(22). pii: 1088. doi: 10.3791/1088.</citation>
    <PMID>19229173</PMID>
  </reference>
  <reference>
    <citation>Lenart L, Balogh DB, Lenart N, Barczi A, Hosszu A, Farkas T, Hodrea J, Szabo AJ, Szigeti K, Denes A, Fekete A. Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling. Diabetologia. 2019 Aug;62(8):1501-1513. doi: 10.1007/s00125-019-4888-z. Epub 2019 May 3.</citation>
    <PMID>31053872</PMID>
  </reference>
  <reference>
    <citation>Li Z, Li Y, Chen L, Chen P, Hu Y. Prevalence of Depression in Patients With Hypertension: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015 Aug;94(31):e1317. doi: 10.1097/MD.0000000000001317. Review. Erratum in: Medicine (Baltimore). 2018 Jun;97(22):e11059.</citation>
    <PMID>26252317</PMID>
  </reference>
  <reference>
    <citation>Lueptow LM. Novel Object Recognition Test for the Investigation of Learning and Memory in Mice. J Vis Exp. 2017 Aug 30;(126). doi: 10.3791/55718.</citation>
    <PMID>28892027</PMID>
  </reference>
  <reference>
    <citation>Menéndez E, Delgado E, Fernández-Vega F, Prieto MA, Bordiú E, Calle A, Carmena R, Castaño L, Catalá M, Franch J, Gaztambide S, Girbés J, Goday A, Gomis R, López-Alba A, Martínez-Larrad MT, Mora-Peces I, Ortega E, Rojo-Martínez G, Serrano-Ríos M, Urrutia I, Valdés S, Vázquez JA, Vendrell J, Soriguer F. Prevalence, Diagnosis, Treatment, and Control of Hypertension in Spain. Results of the Di@bet.es Study. Rev Esp Cardiol (Engl Ed). 2016 Jun;69(6):572-8. doi: 10.1016/j.rec.2015.11.034. Epub 2016 Mar 12. English, Spanish.</citation>
    <PMID>26979767</PMID>
  </reference>
  <reference>
    <citation>Miller RE, Shapiro AP, King HE, Ginchereau EH, Hosutt JA. Effect of antihypertensive treatment on the behavioral consequences of elevated blood pressure. Hypertension. 1984 Mar-Apr;6(2 Pt 1):202-8.</citation>
    <PMID>6724662</PMID>
  </reference>
  <reference>
    <citation>Oliveira PA, Dalton JAR, López-Cano M, Ricarte A, Morató X, Matheus FC, Cunha AS, Müller CE, Takahashi RN, Fernández-Dueñas V, Giraldo J, Prediger RD, Ciruela F. Angiotensin II type 1/adenosine A (2A) receptor oligomers: a novel target for tardive dyskinesia. Sci Rep. 2017 May 12;7(1):1857. doi: 10.1038/s41598-017-02037-z.</citation>
    <PMID>28500295</PMID>
  </reference>
  <reference>
    <citation>Papp M, Willner P, Muscat R. An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology (Berl). 1991;104(2):255-9.</citation>
    <PMID>1876670</PMID>
  </reference>
  <reference>
    <citation>Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol. 2003 Feb 28;463(1-3):3-33. Review.</citation>
    <PMID>12600700</PMID>
  </reference>
  <reference>
    <citation>Rygiel K. Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? An overview of research evidence in the elderly patient population. J Postgrad Med. 2016 Oct-Dec;62(4):242-248. doi: 10.4103/0022-3859.188553. Review.</citation>
    <PMID>27763482</PMID>
  </reference>
  <reference>
    <citation>Taura J, Valle-León M, Sahlholm K, Watanabe M, Van Craenenbroeck K, Fernández-Dueñas V, Ferré S, Ciruela F. Behavioral control by striatal adenosine A(2A) -dopamine D(2) receptor heteromers. Genes Brain Behav. 2018 Apr;17(4):e12432. doi: 10.1111/gbb.12432. Epub 2017 Nov 17.</citation>
    <PMID>29053217</PMID>
  </reference>
  <reference>
    <citation>Williams LJ, Pasco JA, Kessing LV, Quirk SE, Fernandes BS, Berk M. Angiotensin Converting Enzyme Inhibitors and Risk of Mood Disorders. Psychother Psychosom. 2016;85(4):250-2. doi: 10.1159/000444646. Epub 2016 May 27.</citation>
    <PMID>27230871</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Sebastian Videla</investigator_full_name>
    <investigator_title>Head of the Clinical Research Support Unit</investigator_title>
  </responsible_party>
  <keyword>ACEI</keyword>
  <keyword>ARB</keyword>
  <keyword>ACE</keyword>
  <keyword>RAS</keyword>
  <keyword>Angiotension</keyword>
  <keyword>Depression</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

